Cargando…
Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review
Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular A...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380786/ https://www.ncbi.nlm.nih.gov/pubmed/37510788 http://dx.doi.org/10.3390/jcm12144671 |
_version_ | 1785080281847300096 |
---|---|
author | Garweg, Justus G. Keiper, Judith Pfister, Isabel B. Schild, Christin |
author_facet | Garweg, Justus G. Keiper, Judith Pfister, Isabel B. Schild, Christin |
author_sort | Garweg, Justus G. |
collection | PubMed |
description | Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: <Brolucizumab> AND <AMD> AND <intraocular inflammation>. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were 75.9 ± 8.5 years, and 58.5% were female. IOI occurred 41.7 ± 37.5 (median 37.0) days after treatment initiation with 2.0 ± 1.3 (1–6) IVB injections. A mean change in visual acuity of −14.6 ± 21.0 (median −6.5) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was 3.3 ± 6.2 days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of −25.3 ± 27.1 and −2.6 ± 7.3 letters in the chronologically first and last third, respectively, of treated eyes (effect size: r = 0.71; p = 0.006). Functional outcomes markedly improved with increasing experience in managing IOI. |
format | Online Article Text |
id | pubmed-10380786 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-103807862023-07-29 Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review Garweg, Justus G. Keiper, Judith Pfister, Isabel B. Schild, Christin J Clin Med Systematic Review Early poor outcomes of intraocular inflammation (IOI) after intravitreal brolucizumab (IVB) have negatively affected the use of brolucizumab in clinical routine. We wished to identify factors related to the treatment details of IOI involving the posterior segment resulting from IVB for neovascular AMD (nAMD), if these were reported in detail. Articles were retrieved from PubMed, Scopus, ClinicalTrials, and CENTRAL using the following search terms: <Brolucizumab> AND <AMD> AND <intraocular inflammation>. The risk of bias was rated using the JBI Critical Appraisal Tool. We included 31 reports (41 patients and 46 eyes). Patients were 75.9 ± 8.5 years, and 58.5% were female. IOI occurred 41.7 ± 37.5 (median 37.0) days after treatment initiation with 2.0 ± 1.3 (1–6) IVB injections. A mean change in visual acuity of −14.6 ± 21.0 (median −6.5) letters was reported. The mean time from first IOI signs to the initiation of any anti-inflammatory treatment was 3.3 ± 6.2 days, with 63% of the patients receiving systemic corticosteroids as standard treatment. Finally, a period effect was observed, with a change in visual acuity of −25.3 ± 27.1 and −2.6 ± 7.3 letters in the chronologically first and last third, respectively, of treated eyes (effect size: r = 0.71; p = 0.006). Functional outcomes markedly improved with increasing experience in managing IOI. MDPI 2023-07-14 /pmc/articles/PMC10380786/ /pubmed/37510788 http://dx.doi.org/10.3390/jcm12144671 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Systematic Review Garweg, Justus G. Keiper, Judith Pfister, Isabel B. Schild, Christin Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title | Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title_full | Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title_fullStr | Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title_full_unstemmed | Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title_short | Functional Outcomes of Brolucizumab-Induced Intraocular Inflammation Involving the Posterior Segment—A Meta-Analysis and Systematic Review |
title_sort | functional outcomes of brolucizumab-induced intraocular inflammation involving the posterior segment—a meta-analysis and systematic review |
topic | Systematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380786/ https://www.ncbi.nlm.nih.gov/pubmed/37510788 http://dx.doi.org/10.3390/jcm12144671 |
work_keys_str_mv | AT garwegjustusg functionaloutcomesofbrolucizumabinducedintraocularinflammationinvolvingtheposteriorsegmentametaanalysisandsystematicreview AT keiperjudith functionaloutcomesofbrolucizumabinducedintraocularinflammationinvolvingtheposteriorsegmentametaanalysisandsystematicreview AT pfisterisabelb functionaloutcomesofbrolucizumabinducedintraocularinflammationinvolvingtheposteriorsegmentametaanalysisandsystematicreview AT schildchristin functionaloutcomesofbrolucizumabinducedintraocularinflammationinvolvingtheposteriorsegmentametaanalysisandsystematicreview |